Contingent Consideration - Additional Information (Detail) - USD ($)				2 Months Ended	6 Months Ended
	Apr. 26, 2022	Nov. 19, 2020	Jul. 12, 2019	Nov. 19, 2020	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Common stock issued related to contingent consideration liability					$ 6,176,000
Estimated future contingent consideration						$ 5,270,000	$ 6,090,000	$ 5,390,000
Change in value of contingent consideration for acquired in-process research and development					$ 86,000	$ (120,000)
Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Common stock issued related to contingent consideration liability		$ 13,600,000
Shares issued for contingent milestone payment		1,694,906
Period for submission of clinical trial notification		60 days
Submission date of clinical trial notification		Oct. 29, 2020
Clinical Trial Notification [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Change in value of contingent consideration for acquired in-process research and development				$ 5,400,000
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date			Jul. 08, 2019
Unregistered shares of common stock			1,887,250
Up-front consideration			$ 5,000,000.0
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 5,000,000.0
Estimated future contingent consideration term			60 days
Number of consecutive trading days			20 days
Consideration amount			$ 2.95
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 3,000,000.0
Estimated future contingent consideration term			60 days
Number of consecutive trading days			20 days
Consideration amount			$ 3.54
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 80,000,000.0
License agreement term			10 years
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Contingent consideration, percentage of shares released after three months			50.00%
Contingent consideration, percentage of shares released after six months			50.00%
Spitfire Pharma, Inc. [Member] | Phase Two Milestone [Member]
Business Acquisition [Line Items]
Common stock issued related to contingent consideration liability	$ 7,200,000
Estimated future contingent consideration	$ 0
Consideration amount	$ 8.55
Shares issued for contingent milestone payment	847,444
Change in value of contingent consideration for acquired in-process research and development	$ 1,900,000
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Consideration amount		$ 9.57		$ 9.57
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 88,000,000.0